Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Ponatinib (AP24534) is a novel multitargeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clinically achievable drug levels. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, inc...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gozgit, Joseph M., Wong, Matthew J., Wardwell, Scott, Tyner, Jeffrey W., Loriaux, Marc M., Mohemmad, Qurish K., Narasimhan, Narayana I., Shakespeare, William C., Wang, Frank, Druker, Brian J., Clackson, Tim, Rivera, Victor M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236248/
https://ncbi.nlm.nih.gov/pubmed/21482694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-1044
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky